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Background: Whole pelvis intensity modulated radiotherapy (IMRT) is increasingly being used to treat cervical
cancer aiming to reduce side effects. Encouraged by this, some groups have proposed the use of simultaneous
integrated boost (SIB) to target the tumor, either to get a higher tumoricidal effect or to replace brachytherapy.
Nevertheless, physiological organ movement and rapid tumor regression throughout treatment might substantially
reduce any benefit of this approach.
Purpose: To evaluate the clinical target volume - simultaneous integrated boost (CTV-SIB) regression and motion
during chemo-radiotherapy (CRT) for cervical cancer, and to monitor treatment progress dosimetrically and
volumetrically to ensure treatment goals are met.
Methods and materials: Ten patients treated with standard doses of CRT and brachytherapy were retrospectively
re-planned using a helical Tomotherapy - SIB technique for the hypothetical scenario of this feasibility study. Target
and organs at risk (OAR) were contoured on deformable fused planning-computed tomography and megavoltage
computed tomography images. The CTV-SIB volume regression was determined. The center of mass (CM) was used
to evaluate the degree of motion. The Dice’s similarity coefficient (DSC) was used to assess the spatial overlap of
CTV-SIBs between scans. A cumulative dose-volume histogram modeled estimated delivered doses.
Results: The CTV-SIB relative reduction was between 31 and 70%. The mean maximum CM change was 12.5, 9, and
3 mm in the superior-inferior, antero-posterior, and right-left dimensions, respectively. The CTV-SIB-DSC approached
1 in the first week of treatment, indicating almost perfect overlap. CTV-SIB-DSC regressed linearly during therapy,
and by the end of treatment was 0.5, indicating 50% discordance. Two patients received less than 95% of the
prescribed dose. Much higher doses to the OAR were observed. A multiple regression analysis showed a significant
interaction between CTV-SIB reduction and OAR dose increase.
Conclusions: The CTV-SIB had important regression and motion during CRT, receiving lower therapeutic doses
than expected. The OAR had unpredictable shifts and received higher doses. The use of SIB without frequent
adaptation of the treatment plan exposes cervical cancer patients to an unpredictable risk of under-dosing the
target and/or overdosing adjacent critical structures. In that scenario, brachytherapy continues to be the gold
standard approach.
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Pelvic and para-aortic positive 4
Negative Lymph nodes 1
Myometrial infiltration 7
Median tumor size 5 cm (range 4.5 to 8 cm)
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The whole-pelvis irradiation technique for cervical cancer
has evolved over the last decades with the introduction of
intensity modulated radiotherapy (IMRT). In general, it is
accepted that a dose between 45–50 Gy to the pelvis is the
standard of care. Additional dose escalation is achieved by
3D image-guided conformal brachytherapy. Brachytherapy
boost is the gold standard for women with cervical cancer,
limiting the toxicity to the surrounding normal structures
and achieving excellent tumor control rates. The brachy-
therapy dose distribution is also superior to external beam
radiotherapy (EBRT) boost [1]. More recently, investigators
have proposed the use of IMRT to treat cervical cancer
with the aim of reducing toxicity, and some studies have
reported a significant dose reduction to small bowel, blad-
der and rectum with a subsequent decrease in toxicity [2].
Encouraged by these studies, some groups have explored
the possibility of administering a simultaneous integrated
boost (SIB) to target cervical tumors, with the aim of deli-
vering an accelerated treatment to gross disease [3-5]. The
final purpose of this technique has been either dose escal-
ation to get higher tumoricidal effect or a way to replace
brachytherapy.
Cervical cancers are usually bulky, and evidence shows
rapid tumor reduction over the course of chemo-
radiotherapy (CRT), which raised concerns about mis-
sing the geographical target using IMRT techniques [6-8].
Furthermore, the current target volume of IMRT-SIB
plans is based on a single image set taken at one point be-
fore the start of treatment. Therefore, the initial dosimetry
and dose volume histograms (DVHs) might not necessa-
rily represent the actual dose delivered to the tumor and
organs at risk (OAR), which further adds to the uncertain-
ties in the use of SIB. The purpose of this study is to
evaluate the magnitude of the gross tumor volume (GTV)
regression and the impact that this has on the clinical tar-
get volume-simultaneous integrated boost (CTV-SIB) mo-
tion during CRT. We report the dosimetric consequences
of the anatomical changes after re-contouring the target
and the OAR on each weekly megavoltage computed to-
mography (MV-CT) taken daily for set-up verification to
ensure treatment goals are met.
Materials and methods
Ten women with cervical cancer were retrospectively re-
planned in a hypothetical scenario to study the feasibility of
the SIB technique. Patients’ characteristics are described in
Table 1. They had undergone standard whole pelvis irradia-
tion using helical Tomotherapy (HT) with daily MV-CTs to
a total dose of 50.4 Gy in 28 fractions of 1.8 Gy with con-
comitant weekly cisplatin chemotherapy. It is important to
note that these women were all treated with magnetic re-
sonance imaging (MRI)-guided intracavitary brachytherapy,
and that the SIB technique was carried out only to evaluatethe feasibility of the technique but was finally not imple-
mented to treat these patients. The local ethical committee
approved the study.
Imaging
Each patient underwent a pelvic CT scan (planning-CT)
and MRI before starting CRT. In an attempt to minimize
organ motion and as per standard practice in our depart-
ment, patients received written instructions to use a mild
laxative 48 h before the planning-CT and to drink 400 ml
of water one hour before the CT after voiding completely.
Patients were also advised to follow the same instructions
during treatment. For the planning-CT, the acquisition
parameters were as follows: tension 120 kV, tube rotation
time 1 second, tube current 160 mAs, helical acquisition
with pitch of 0.938, reconstructed image thickness 2 mm.
Patients received intravenous contrast media.
As part of the daily treatment, on-board MV-CTs were
obtained prior to each RT session using HT. The images
were evaluated on-line by the radiation therapist, and if
soft-tissue deviations were identified (due to variations
in bladder or rectal filling), patients were taken off the
treatment and the attending radiation oncologist was
called to advise the patient on how to correct the
physiological deviations of the OAR. Patients were then
treated that same day with a full bladder and an empty
rectum. A new MV-CT was then taken to ensure the
correct set-up. In this latter situation, the latest correct
MV-CT (full bladder – empty rectum) was used for this
study. All MV-CTs were imported to Velocity Advanced
Imaging Software (Velocity Medical Solutions, Atlanta,
GA) and deformable fused with the planning-CT.
Figure 1 Standardized guidelines on contouring the clinical
target volume - simultaneous integrated boost (CTV-SIB) on
the planning-CT and weekly MV-CTs. Guidelines were adapted
from Viswanathan et al. Axial and sagittal view of weekly contouring
in one of the patients. The CTV-SIB structures included were: In red:
The cervix containing the tumor. In yellow: Parametriums were
divided as: • If inner half invasion: Butterfly shape structure <2 cm
from cervix edge. • If outer half invasion: Butterfly shape structure
> 2 cm from cervix edge. In green (sagittal view): Corpus uteri. • If
there was myometrial infiltration the entire corpus uteri was
included. • If there was no myometrial infiltration, a 2-cm expansion
was added from the proximal extend of the superior cervix edge or
to a point at which volume expands (indicating presence of uterine
tissue – where the uterine cavity appears). The vagina was
contoured as a 2 cm expansion inferior to cervix edge.
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did not have an MRI during the course of CRT.
Delineation of clinical target volume (CTV) and planning
target volume (PTV)
For accuracy on contouring, the T2-weighted MRI image
sets at diagnosis were rigidly fused to the baseline
planning-CT images using Velocity Advanced Imaging
Software. The target and the OAR were contoured on the
planning-CT and on each weekly MV-CT. All targets and
OAR were contoured by a radiation oncologist (EDS)
before being reviewed by a second investigator (FH), both
with an experience of seven years in treating gynecological
malignancies. In case of doubt or disagreement, a radiolo-
gist with ten years experience in gynecological cancer
(JYM) provided precision in defining the anatomical
structures.
The IMRT consortium guidelines were used to contour
the pelvic CTV [9]. According to the same guidelines, a
1.5-cm uniform margin was added around the CTV to
obtain the pelvic planning target volume (pPTV). The
nodal CTV (nCTV) was delineated according to published
guidelines [10]. A 7-mm uniform margin was added to the
nCTV to obtain the nodal PTV (nPTV) [11]. No consensus
exists on the structures to be included in the CTV-SIB. We
encountered important limitations when contouring struc-
tures on MV-CT imaging due to low soft-tissue contrast.
To overcome these limitations we used previously pub-
lished guidelines on CT-based contouring for brachythe-
rapy in cervical cancer [12]. Figure 1 describes the
structures included and shows the contour delineation in
one of the patients. A 1-cm uniform margin was added to
the CTV-SIB to obtain the PTV-SIB. We chose this mar-
gin knowing from previous publications that a margin
smaller than 1-cm might not achieve good target cover-
age, whilst with a larger margin the constraints of the
OAR would not be respected [13].
Delineation of OAR
The OAR were contoured on the fused planning-CT/MRI
image sets and then re-contoured for comparisons on each
weekly MV-CT. The delineated OAR were bladder, recto-
sigmoid up to the sigmoid loop to the level of sacrum 1–2,
and the small bowel as a whole peritoneal cavity or space
that individual loops could occupy during treatment. No
margin for planning organs at risk volume was applied.
RT Planning
The prescribed dose to pPTV was 50.4 Gy in 28 fractions
of 1.8 Gy. The dose prescribed to PTV-SIB was 59.36 Gy
delivered in 2.12 Gy per fraction in 28 fractions. We did
not increase the dose to the PTV-SIB to more than 60 Gy
because this would have had a detrimental effect on the
OAR.The primary target coverage objectives were: 98% of
CTV-SIB to be covered by 98% of the prescribed dose, and
98% PTV-SIB to be covered by 95% of the prescribed dose.
Dose objectives for the OAR were based on the RTOG
0415 protocol, and were kept as low as possible without
compromising PTV coverage. As the nodal volume is rela-
tively fixed to bone, the nCTV was assumed not to change
during the course of treatment, receiving its planned dose,
and is not assessed in this study. The IMRT plans were per-
formed on the Tomotherapy TPS (TomoTherapy Inc.,
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0.287.Dose accumulation
Dosimetric changes can occur due to either external
anatomical changes or internal organ motion. In this
study, our aim was to put into perspective the organ
motion without considering the external anatomical
changes. Therefore, we selected patients who did not
have a significant change in their outer anatomy due to
weight change and we assumed that external geometry
did not change. Following that assumption, the dose dis-
tributions obtained from the planning-CT were fused to
each weekly MV-CT using a deformable registration al-
gorithm, assuring that the deformable dose matrix was
applied in the same voxel position.
The total dose received by the CTV-SIB and the OAR
over the course of treatment was calculated by plotting
the cumulative DVH for each patient structure.Volumetric geometrical and positional analyses
To determine the displacements of the CTV-SIB during
treatment, the Velocity software was used to place a
geometric center of mass (CM) on each CTV-SIB. The
coordinates of the CTV-SIB-CM on the planning-CT were
then compared with the coordinates of all other CTV-SIB
geometric centers for each weekly MV-CT. We determined
the maximal displacements in right-left (x), anterior-
posterior (y) and superior-inferior (z) directions. The
maximum CTV-SIB displacements were measured for each
patient, and the mean maximum CTV-SIB - displacements
were calculated for the entire cohort. We also performed
the same analysis for the OAR.
For each patient the spatial overlap between any two
CTV-SIB contours was calculated using the Dice’s simi-
larity coefficient (DSC) [14]. When the CTV-SIB struc-
tures on the planning-CT overlap perfectly with those
on the MV-CTs, the DSC is 1. Complete discordance
gives a value of 0. Values of DSC less than 0.5 indicate
discordance exceeding 50%.Statistics
Multivariate analysis of variance (MANOVA) was used
to compute the statistical differences in volume changes
during treatment. The dosimetric consequences of vo-
lume change after weekly re-contouring were assessed
by comparing the planned vs. delivered doses using a
paired Student’s t-test.
A multiple regression analysis was used to determine
which movement/volume factors contributed the most
to the dose received to a given structure.Results
CTV-SIB regression and motion
The weekly MV-CTs showed important regression of the
CTV-SIB during the course of CRT. The mean CTV-SIB
was 237.38 cc (range 69.3 to 518) on the planning-CT and
112.55 cc (range 26.8 to 199.2) on the MV-CT at the end of
CRT. The relative reduction in the CTV-SIB from baseline
to the end of CRT was 31-70%. (MANOVA, p = 0.0002).
(Figure 2) The median number of MV-CTs (correct after
set-up verification) obtained per patient was 6 (range 4 to 6
scans).
The mean maximum change in CTV-SIB-CM position
for the entire cohort was 4.7 mm anteriorly (range 0 to
13.4), -8 mm posteriorly (range −0.6 to −15.6), -4.2 mm
superiorly (range −1.4 to −15), 4.7 mm inferiorly (range 0
to 15.5), -3 mm right-laterally (range −0.4 to −9.7), and
2 mm left-laterally (range 0 to 7.8) (Figure 3A).
Examining the individual patients represented in
Figure 3B, we observe the intricate variation of the CTV-
SIB-CM with mean weekly displacements up to 13 mm,
10 mm, and 4 mm in the anterior-posterior, superior-
inferior, and right-left lateral axes, respectively.
The mean weekly DSC for the entire cohort showed a
linear regression during the course of CRT (Figure 4).
Interestingly, the mean weekly DSC during the first week
of treatment was 0.8 (range 0.55 to 0.91) indicating a
mean discordance of 20% between any two CTV-SIB
contours under comparison. In contrast, at the end of
CRT the mean weekly reduction in the DSC for the en-
tire cohort was 0.5 (range 0.41 to 0.55), indicating more
than 50% discordance, (MANOVA, p < 0.0001).
OAR volume changes
Despite bowel and bladder preparation, important va-
riation occurred during treatment. The maximal relative
changes in bladder, recto-sigmoid, and bowel volume
compared to baseline were 34 to 91%, 8 to 73.8%, 5 to
52%, respectively.
Significant changes of volume were seen over time.
Bladder volume decreased significantly (MANOVA,
p = 0.0001). The volume of recto-sigmoid and bowel
increased significantly during the treatment period
(MANOVA, p < 0.0001).
Planned vs. delivered (accumulated) dose to CTV-SIB
In the patient cohort, the mean accumulated CTV-SIB
dose to 98% volume (D98) decreased from 59.74 Gy to
58.89 Gy, (p = 0.54). However, in two individual patients,
the CTV-SIB failed to meet the minimum acceptable
95% dose criteria. (Additional file 1: Appendix I-A). Be-
ginning at the second week these two patients had a
reduction in the CTV-SIB. As treatment progressed, the
uterus became retroverted favoring the posterior move-





















Figure 2 Changes in the clinical target volume - simultaneous integrated boost (CTV-SIB) for each patient during the course of chemo-
radiotherapy (CRT). The volume of the CTV-SIB is plotted as a percentage of the CTV-SIB from the start of CRT. Percentages are plotted against
time in weeks. Week 0 corresponds to measurements taken on the planning-CT before the start of CRT. Week 1–6 are measurements from the
weekly MV-CTs.
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PTV-SIB. These regions of 20 and 37 cc would have
been under-dosed during most of the treatment with an
accumulated D98 of 48.26 Gy and 43.13 Gy, respectively.
(Additional file 2: Appendix II).
A multiple regression analysis (Table 2) shows the
significant inter-relation between organ movement and
CTV-SIB under-dosage. When the rectum moves ante-
riorly or reduces in volume the CTV-SIB receives a
significantly lower dose (p = 0.029 and p = 0.01, respect-
ively) When the CTV-SIB reduces in volume the DSC
goes significantly down (p = 0.005).Planned vs. delivered (accumulated) doses to OAR
Looking at the entire cohort, the planned and deli-
vered (accumulated) doses to recto-sigmoid, bladder
and bowel were not statistically different when com-
pared to the original planning scenario (p = 0.96,
p = 0.78, and p = 0.23, respectively). However, when
we measure the OAR volumes exposed to more than
90% of the prescribed dose, 59.36 Gy (V53.4), indivi-
dual patients had an increase in this volume.
(Additional file 1: Appendix I-B). Taking all patients
as a group, the V53.4 for bladder and bowel increased
from 41.6% to 50.7% (p = 0.28), and from 7% to 14%
(p = 0.01), respectively.
A multiple regression analysis (Table 2) shows the sig-
nificant interplay between organ motion and CTV-SIB
movements. When the bladder reduces in volume or
moves anteriorly, the dose to the bowel increases signifi-
cantly (p=0.0046, and p=0.01, respectively). When the
CTV-SIB moves anteriorly, creating more space for the
recto-sigmoid, the rectal dose goes up (p < 0.00001). In
the same way, the bladder dose increases when the
CTV-SIB reduces in volume (p=0.01).Discussion
IMRT has been shown to reduce treatment-induced to-
xicity but its use in cervical cancer has been limited be-
cause of significant organ movement [6]. Nevertheless,
prompted by technological advances, some groups have
speculated that SIB can replace the use of brachytherapy
or eventually increase tumoricidal doses to the target
[3,5,15]. Recent publications, mainly focused on
optimization analysis, have proposed the use of SIB to
treat cervical cancer [4]. However, the impact of organ
motion on target coverage was not evaluated. Therefore,
our study provides comprehensive information about
the movement of the target and the OAR when SIB is
used, with special focus on the dosimetrical conse-
quences of this movement in women who underwent re-
petitive images during treatment.
We showed that the site and volume of the CTV-SIB
changes significantly during CRT. These results are con-
sistent with findings from other groups documenting a
pelvic CTV relative reduction between 7-80% from base-
line to the end of treatment due to tumor shrinkage [8].
Van de Bunt et al. observed rapid tumor regression
using MRI scans before and after 30 Gy with a mean re-
duction in cervix tumor volume of 79% after three weeks
of therapy [16]. Our results demonstrated a large va-
riation of the CTV-SIB-CM, in the order of centimeters
in some cases, with an important impact on the DSC.
This is explained by geometrical changes in the position
of the cervix and corpus uteri as well as variations in
bladder and rectal filling. Chan et al. studied the internal
movement of the tumor, cervix, and uterus using weekly
cine-MRIs and a point of interest analysis (POI). The
fundus POI drifted 1.5 cm caudally during CRT, and the
cervical canal 1 cm. [7] Lee et al. used a metallic ring
that was part of a brachytherapy uterine sleeve as a sur-
rogate for cervix position. They reported motion in the
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x-axis: right-left lateral, y-axis: anterior-posterior, z-axis: superior-inferior
Figure 3 Clinical target volume - simultaneous integrated boost (CTV-SIB) – center of mass (CM) displacements in millimeters (mm)
from the original planning-CT center of mass position. A) Mean maximal displacements of the CTV-SIB-CM in each dimension. B) Mean
weekly CM displacements in individual patients.
Herrera et al. Radiation Oncology 2013, 8:5 Page 6 of 10
http://www.ro-journal.com/content/8/1/5medio-lateral, antero-posterior, and supero-inferior
directions of 10, 16, and 8 mm, respectively [17]. This
motion is in line with that observed in our study. How-
ever, it is important to recognize that the results of our
study depend also on the CTV-SIB definition that we
used and might not translate to other situations. It is im-
portant to note that in most of our patients a large area
of corpus uteri was incorporated into the CTV-SIB. This
part of the uterus is the most mobile one and might
have contributed to an increase in the CM movement as
well as a decrease in the DSC. Nevertheless, our CTV-
SIB definition is consistent with recent published guide-
lines of brachytherapy [18,19]. The use of fiducialmarkers has also been proposed to define the SIB in cer-
vical cancer [4]. However, systematic and random displa-
cements of the markers relative to bony anatomy have
been reported to be up to 1 cm [20].
We observed two patients with important target-
missing with parts of the CTV-SIB moving outside
the PTV-SIB. These patients would have needed pos-
terior PTV-SIB margins of at least 1.5 cm, which
would have been detrimental for the OAR, especially
in the context of relatively high doses per fraction.
The use of daily imaging would not have compen-
sated for the magnitude of the movement, and pe-

























Figure 4 Mean weekly Dice’s similarity coefficient (DSC) for the entire cohort. Triangles represent mean values; the extensions of the lines
represent range fluctuations.
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consequences of this target-missing might not be sig-
nificant as some portions of the CTV-SIB continued
to receive at least some dose, and remained well con-
tained in the pelvis PTV. This might explain why pre-
vious studies of dose escalation with SIB and brachytherapy
boost have so far reported optimal local control rates
[4,21]. Nevertheless, target-missing with SIB can be clinic-
ally important if clinicians decide to apply lower doses of
brachytherapy or simply if brachytherapy is withheld, which
might expose patients to the catastrophic consequences of
a local recurrence. Recent reports where radiation at doses
of 54–70 Gy was applied using 3D-EBRT techniques, in
patients regarded as inappropriate for brachytherapy, indi-
cated an excessive local failure rate of 48% [22].
For this feasibility study, a relatively conservative SIB
dose was modeled (from 50.4 to 59.4 Gy). This dose was
chosen considering the large volume of PTV-SIB andTable 2 Multiple regression analysis
CTV under-dosage p-value
Rectum moved anteriorly 0.029
Rectum reduced in volume 0.01
Reduction in the Dice’s coefficient 0.005
Bowel doses increase p-value
Bladder moved anteriorly 0.01
Bladder reduced in volume 0.0046
Rectal doses increase p-value
Rectal volume increased 0.0026
CTV-SIB moved anteriorly 0.00001
Bladder doses increase p-value
Bladder moved posteriorly 0.01
CTV-SIB reduced in volume 0.01
Independent factors contributing to the clinical target volume - simultaneous
integrated boost (CTV-SIB) under-dosage and organs at risk (OAR) over-
dosage.the total amount of healthy tissue exposed. It has been
previously published that large volumes in the pelvic
region receiving more than 60 Gy correlates with
increased pelvic side effects [23]. The SIB dose is
another unresolved issue that should be considered
before implementing this technique to treat cervical
cancer. It must be remembered that squamous cell
carcinoma of the cervix shows dose dependency with a
greater response and local control with higher doses of
radiation [24]. The use of relatively low doses per frac-
tion with SIB might eventually compromise outcome.
Conversely, in brachytherapy, the dose to the GTV is
higher owing to the vicinity of the sources, and the doses
to the OAR have a steep dose gradient. In brachythe-
rapy, target coverage is not compromised as individual
MRI-based plans are performed before each intracavitary
insertion [25]. Furthermore, an IMRT-SIB boost with
lower doses per fraction compared to brachytherapy
should not compromise the total duration of treatment
time which has been found to have a significant effect
on pelvic control. Fyles et al. found that in 830 patients
with cervical cancer treated by radical radiation therapy
the loss of control was 1% per day of treatment
prolongation beyond 30 days [26]. In addition, important
concepts such as the need for generous margins make
IMRT-SIB not comparable to brachytherapy. Even
though, IMRT has challenged brachytherapy in different
studies [27]. For example, tomotherapy boost was
compared with a simple brachytherapy technique based
on a Fletcher-Suit applicator [28]. Molla et al. reported
on 15 patients who received IMRT boost as an alterna-
tive to brachytherapy [29]. The conclusions drawn from
these studies were that IMRT allowed better OAR-
sparing and more homogeneous dose distributions.
However, these conclusions were biased because IMRT
was compared with old brachytherapy techniques.
Certainly, brachytherapy is much less homogeneous as
the highest dose volume (>200% of the dose) is located
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high doses delivered in the central part of the tumor are
the key for the success of this treatment modality. More
recent advances attempted a comparison between high-
tech EBRT and MRI-guided brachytherapy in locally
advanced cervical cancer [30]. Georg et al. compared
IMRT with photons and protons to deliver the highest
possible dose to the PTV while respecting the dose to
1 cc (D1cc) and 2 cc (D2cc) limits of brachytherapy using
the same fractionation (4 fractions of 7 Gy). Nine
patients treated with intracavitary or interstitial brachy-
therapy were selected and re-planned using 3 and 5 mm
margins around the high-risk and intermediate-risk
CTV to construct the external beam-PTV. In this study,
when the brachytherapy dose constraints were applied
(D2cc and D1cc) to the IMRT plans, the minimal dose
that covered 90% of the high-risk and intermediate-risk
external beam-PTVs was lower for the IMRT-plans. On
the other hand, volumes receiving 60 Gy were approxi-
mately twice as large for IMRT compared to brachythe-
rapy [1]. In summary, these studies showed that for
cervical cancer boost treatments, IMRT is inferior to
modern brachytherapy.
In the context of significant intra-patient variability
with complex tumor and organ dynamics, we believe
there is a place for improvement through the use of
adaptive planning strategies using deformable registra-
tion. In the series of the Princess Margaret Hospital, 33
cervical cancer patients were evaluated with a 3 mm
PTV margin with and without weekly adaptive re-
planning [8,31]. In the non-adaptive scenario, 27%
patients failed acceptable target coverage; this percent-
age was reduced to 3% when an adaptive strategy was
applied with significant sparing to the OAR. In this
regard, our dose accumulation relies upon perfect exter-
nal anatomy configuration. This ideal scenario might be
very different from real practice where the dose deliv-
ered to the tumor and the OAR might differ from the
planned one because the patient’s geometry and internal
anatomy varies over the course of treatment. This major
technological challenge implies the use of deformable regis-
tration algorithms combined with adaptive re-planning.
Nevertheless, we think that using accumulated doses
derived from our deformable registration algorithm was the
most suitable methodology to evaluate volumetric and dosi-
metric uncertainties, without taking into account the
changes in the patients’ external geometry.
An important question that we should be able to answer
in the near future is whether image-guided adaptive exter-
nal beam radiotherapy (IGART) can be combined with
image-guided adaptive brachytherapy (IGAB). With this ap-
proach, IGAB could utilize the dose reduction in the OAR
achieved by IGART, in order to further improve the thera-
peutic ratio and to deliver a personalized radiation dose toeach patient with an opportunity for dose escalation. For
that purpose composite IMRT and brachytherapy plans
should be fully integrated, and voxel by voxel tracking from
both techniques could provide an advantage in the treat-
ment of these women.
This study has several limitations. First, we retrospect-
ively evaluated the feasibility of SIB in cervical cancer using
weekly MV-CT images rather than MRI to contour cervical
boundaries. The MV-CTs are part of the daily images taken
for set-up verification with HT and the study was done in
this way for practical reasons. The use of MV-CTs might
have led to overestimation of the size of the CTV-SIB,
overshadowing the already significant results. Previous
work on cervical cancer patients has shown that MV-CT
guidance allows the identification and contouring of the
cervix with minimal intra- and inter-observer variability
among the investigators [32]. In addition, the data obtained
from our weekly MV-CTs were extrapolated to the whole
course of treatment, which might have produced an
overestimation of systematic errors. The intra-fraction mo-
tion of the target was assumed to be zero which might have
further under-estimated random errors. The set-up errors
were assumed to be negligible because of daily online
MV-CTcorrections.
Conclusions
The structures contained in the CTV-SIB show a significant
regression during the course of CRT. Uterus and OAR
change in volume, shape and location along the course of
treatment. These unpredictable changes make the delivery
of IMRT and particularly SIB challenging. The use of daily
MV-CT imaging and considerable PTV margins in the
absence of an adaptive strategy could not compensate for
the CTV-SIB positional changes with therapeutic doses
lower than expected and higher doses to the OAR. In this
context, it is nearly impossible to perform an SIB with a
dose comparable to brachytherapy. SIB has to assure tumor
control without significantly increasing the irradiation to
normal tissues, and using adaptive planning strategies
coupled with deformable registration are expected to add a
significant improvement in the delivery of IMRT-SIB. How-
ever, in the absence of deformable registration and adaptive
re-planning, the use of IMRT-SIB should be avoided.
Brachytherapy continues to be the gold standard.
Additional files
Additional file 1: Appendix 1. A)Histograms of planned vs.
accumulated delivered doses to clinical target volume – simultaneous
integrated boost (CTV-SIB) for each patient in the study. ICRU 50 specifies
the acceptable dose range as 95–107% of the prescribed dose. The
arrows indicate patients who received less than 95% of the prescribed
dose. B)Histograms of planned vs. accumulated delivered doses to the
OAR in individual patients. In the y-axis is the tissue volume receiving
more than 90% of the prescribed dose, 59.36 Gy (V53.4).
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http://www.ro-journal.com/content/8/1/5Additional file 2: Appendix 2. Target motion: Axial and sagittal view in
one patient. In both figures the blue contour is the pre-treatment clinical
target volume-simultaneous integrated boost (CTV-SIB) with a 1-cm
margin planning target volume (PTV-SIB) black contour encompassed by
the 95% isodose curve. For this patient the PTV-SIB does not cover a
posterior shift of the CTV-SIB from week 2 until the end of treatment
(lighter contours). In the MATLAB graphic we observe the three
dimensional movement of the vectors in this same patient.
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